Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

14 Nov 2017

• By Emily Hayes

In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival endpoint regardless of PD-L1 expression, supporting a bid for expanded labeling.

Bristol’s IO Pathways In Development — Bristol is developing many new immuno-oncology mechanisms, some of which were showcased at the SITC meeting in November. • Source: Bristol-Myers Squibb

Bristol-Myers Squibb Co. got a boost with promising data for its PD-1 inhibitor Opdivo in combination with drugs in a number of different classes, including the company's own assets – the CTLA-4 inhibitor Yervoy in first-line kidney cancer and its IDO inhibitor BMS 986205 in bladder cancer – plus Five Prime Therapeutics Inc.'s anti-CSF cabiralizumab in pancreatic cancer.

Bristol's highlights included an exploratory analysis of the Phase III CheckMate 214 study of Opdivo (nivolumab) with Yervoy (ipilimumab) in...